Allosteric modulation of seven transmembrane spanning receptors: Theory, practice, and opportunities for central nervous system drug discovery

Journal of Medicinal Chemistry

Volumn 55, Issue 4, 2012, Pages 1445-1464

  Melancon, Bruce J ^a,b   Hopkins, Corey R ^a,b,c   Wood, Michael R ^a,b,c   Emmitte, Kyle A ^a,b,c   Niswender, Colleen M ^a,b   Christopoulos, Arthur ^d   Conn, P Jeffrey ^a,b   Lindsley, Craig W ^a,b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 METHOXYPHENYL) N (3 PHENYLPROPYL)ETHYLAMINE; 2 AMINO 3 (3,4 DICHLOROBENZOYL) 4,5,6,7 TETRAHYDROBENZO[B]THIOPHENE; 2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 4 ANILINO 2 CYCLOPENTYLIMIDAZO[4,5 C]QUINOLINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; ACETYLSALICYLIC ACID; ALCURONIUM; AMILORIDE DERIVATIVE; AMIODARONE; ANCRIVIROC; ANTALARMIN; APLAVIROC; BENZODIAZEPINE DERIVATIVE; BRUCINE; CANNABIDIOL; CINACALCET; CYCLAMATE SODIUM; G PROTEIN COUPLED RECEPTOR; HEPARIN; MARAVIROC; NAVARIXIN; PLERIXAFOR; REPARIXIN; SALICYLATE SODIUM; SEVEN TRANSMEMBRANE SPANNING RECEPTOR; STAUROSPORINE; TECALCET; TRICHOSANTHIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC;

ALLOSTERISM; CENTRAL NERVOUS SYSTEM; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; NONHUMAN; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; DRUG DISCOVERY; HUMANS; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, MUSCARINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84857375139     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201139r     Document Type: Review

References (230)

1. Kenakin, T.; Miller, L. J. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery Pharmacol. Rev. 2010, 62, 265-304
2. Umbarger, H. E. Evidence for a negative feedback mechanism in the biosynthesis of isoleucine Science 1956, 123, 848
3. Fenton, A. W. Allostery: an illustrated definition for the "second secret of life" Trends Biochem. Sci. 2008, 33, 420-425
4. Conn, P. J.; Christopolous, A.; Lindsley, C. W. Allosteric modulators of GPCRs as a novel approach to treatment of CNS disorders Nat. Rev. Drug Discovery 2009, 8, 41-54
5. Bridges, T. M.; Lindsley, C. W. G-protein coupled receptors: from classical modes of modulation to allosteric mechanisms ACS Chem. Biol. 2008, 3, 530-542
6. Christopoulos, A.; Kenakin, T. G protein-coupled receptors allosterism and complexing Pharmacol. Rev. 2002, 54, 323-374
7. Christopoulos, A. Allosteric binding sites on cell surface receptors: novel targets for drug discovery Nat. Rev. Drug Discovery 2002, 1, 198-210 (Pubitemid 37361423)
8. Kenakin, T. P. 7TM receptor allostery: putting numbers to shapeshifting proteins Trends Pharmacol. Sci. 2009, 30, 460-469
9. Mohler, H. F.; Fritschy, J. M.; Rudolph, U. A new benzodiazepine pharmacology J. Pharmacol. Exp. Ther. 2002, 300, 2-8 (Pubitemid 34028501)
10. Langmead, C. J.; Christopoulos, A. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox Trends Pharmacol. Sci. 2006, 27, 475-481 (Pubitemid 44233695)
11. May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 2007, 47, 1-51 (Pubitemid 46277033)
12. Lewis, J. A.; Lebois, E. P.; Lindsley, C. W. Allosteric modulators of kinases and GPCRs. Design principles and structural diversity Curr. Opin. Chem. Biol. 2008, 12, 269-279
13. Scott, S. A.; Selvy, P. E.; Buck, J.; Cho, H. P.; Criswell, T. L.; Thomas, A. L.; Armstrong, M. D.; Arteaga, C.; Lindsley, C. W.; Brown, H. A. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness Nat. Chem. Biol. 2009, 5, 108-117
14. Hogg, R. C.; Buisson, B.; Bertrand, D. Allosteric modulation of ligand-gated ion channels Biochem. Pharmacol. 2005, 70, 1267-1276 (Pubitemid 41386526)
15. Bogoyevitch, M. A.; Fairlie, D. P. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding Drug Discovery Today 2007, 12, 622-633 (Pubitemid 47238645)
16. Deupi, X.; Standfuss, J. Strucutral insights into agonist-induced activation of G-protein-coupled receptors Curr. Opin. Struct. Biol. 2011, 21, 541-551
17. Li, J.; Edwards, P. C.; Burghammer, M.; Villa, C.; Schertler, G. F. Structure of bovine rhodopsin in a trigonal crystal form J. Mol. Biol. 2004, 343, 1409-1438 (Pubitemid 39387834)
18. Okada, T.; Sugihara, M.; Bondar, A. N.; Elstner, M.; Entel, P.; Buss, V. The retinal conformation and its environment in rhodopsin in light of a new 2.2 Å crystal structure J. Mol. Biol. 2004, 342, 571-583 (Pubitemid 39149759)
19. Standfuss, J.; Xie, G.; Edwards, P. C.; Burghammer, M.; Oprian, D. D.; Schertler, G. F. Crystal structure of a thermally stable rhodopsin mutant J. Mol. Biol. 2007, 372, 1179-1188 (Pubitemid 47381449)
20. Kobilka, B.; Schertler, G. F. New G-protein-coupled receptor crystal structures: insights and limitations Trends Pharmacol. Sci. 2008, 29, 79-83
21. Tate, C. G.; Schertler, G. F. Engineering G protein-coupled receptors to facilitate their structure determination Curr. Opin. Struct. Biol. 2009, 19, 386-395
22. Warne, T.; Serrano-Vega, M. J.; Baker, J. G.; Moukhametzianov, R.; Edwards, P. C.; Henderson, R.; Leslie, A. G.; Tate, C. G.; Schertler, G. F. Structure of a beta1-adrenergic G-protein-coupled receptor Nature 2008, 454, 486-491
23. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor Science 2007, 318, 1258-1265 (Pubitemid 350172884)
24. Jaakola, V. P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.; Chien, E. Y.; Lane, J. R.; Ijzerman, A. P.; Stevens, R. C. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist Science 2008, 322, 1211-1217
25. Wu, B.; Chien, E. Y.; Mol, C. D.; Fenalti, G.; Liu, W.; Katritch, V.; Abagyan, R.; Brooun, A.; Wells, P.; Bi, F. C.; Hamel, D. J.; Kuhn, P.; Handel, T. M.; Cherezov, V.; Stevens, R. C. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists Science 2010, 330, 1066-1071
26. Chien, E. Y.; Liu, W.; Zhao, Q.; Katritch, V.; Han, G. W.; Hanson, M. A.; Shi, L.; Newman, A. H.; Javitch, J. A.; Cherezov, V. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist Science 2010, 330, 1091-1095
27. Park, J. H.; Scheerer, P.; Hofmann, K. P.; Choe, H. W.; Ernst, O. P. Crystal structure of the ligand-free G-protein-coupled receptor opsin Nature 2008, 454, 183-187 (Pubitemid 351969893)
28. Scheerer, P.; Park, J. H.; Hildebrand, P. W.; Kim, Y. J.; Krauss, N.; Choe, H. W.; Hofmann, K. P.; Ernst, O. P. Crystal structure of opsin in its G-protein-interacting conformation Nature 2008, 455, 497-502
29. Standfuss, J.; Edwards, P. C.; D'Antona, A.; Fransen, M.; Xie, G.; Oprian, D. D.; Schertler, G. F. The structural basis of agonist-induced activation in constitutively active rhodopsin Nature 2011, 471, 656-660
30. Choe, H. W.; Kim, Y. J.; Park, J. H.; Morizumi, T.; Pai, E. F.; Krauss, N.; Hofmann, K. P.; Scheerer, P.; Ernst, O. P. Crystal structure of metarhodopsin II Nature 2011, 471, 651-655
31. Rasmussen, S. G.; Choi, H. J.; Fung, J. J.; Pardon, E.; Casarosa, P.; Chae, P. S.; Devree, B. T.; Rosenbaum, D. M.; Thian, F. S.; Kobilka, T. S. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor Nature 2011, 469, 175-180
32. Xu, F.; Wu, H.; Katritch, V.; Han, G. W.; Jacobson, K. A.; Gao, Z. G.; Cherezov, V.; Stevens, R. C. Structure of an agonist-bound human A2A adenosine receptor Science 2011, 332, 322-327
33. Ma, L.; Seager, M.; Wittman, M.; Bickel, N.; Burno, M.; Jones, K.; Graufelds, V. K.; Xu, G.; Pearson, M.; McCampbell, A.; Gaspar, R.; Shughrue, P.; Danzinger, A.; Regan, C.; Garson, S.; Doran, S.; Kreatsoulas, C.; Veng, L.; Lindsley, C. W.; Shipe, W.; Kuduk, S.; Jacobson, M.; Sur, C.; Kinney, G.; Seabrook, G. R.; Ray, W. J. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation Proc. Natl. Acad Sci. U.S.A. 2009, 106, 15950-15955
34. Li, Y. W.; Fitzgerald, L.; Wong, H.; Lelas, S.; Zhang, G.; Lindner, M. D.; Wallace, T.; McElroy, J.; Lodge, N. J.; Gilligan, P.; Zaczek, R. The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists CNS Drug Rev. 2005, 11, 21-52 (Pubitemid 40577944)
35. Gasparini, F.; Lingenhohl, K.; Stoehr, N.; Flor, P. J.; Heinrich, M.; Vranesic, I.; Biollaz, M.; Allgeier, H.; Heckendorn, R.; Urwyler, S.; Varney, M. A.; Johnson, E. C.; Hess, S. D.; Rao, S. P.; Sacaan, A. I.; Santori, E. M.; Velicelebi, G.; Kuhn, R. 2-Methyl-6-(phenylethynyl)-pyrimidine (MPEP), a potent, selective and systemically active mGluR5 receptor antagonist Neuropharmacology 1999, 38, 1493-1503 (Pubitemid 29457731)
36. Lindsley, J. E.; Rutter, J. Whence cometh the allosterome? Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 10533-10535 (Pubitemid 44078012)
37. Urwyler, S. Allosteric modulation of Family C G protein-coupled receptors: from molecular insights to therapeutic perspectives Pharmacol. Rev. 2011, 63, 59-126
38. Tsai, G.; Coyle, J. T. Glutamatergic mechanisms in schizophrenia Annu. Rev. Pharmacol. Toxicol. 2002, 42, 165-179 (Pubitemid 34160524)
39. 2+-sensing receptor by l -amino acids enhances ERK1/2 phosphorylation Biochem. J. 2007, 404, 141-149 (Pubitemid 46788094)
40. Massot, O.; Rosselle, J. C.; Fillion, M. P.; Grimbaldi, B.; Cloez-Tayarani, I.; Fugelli, A.; Prudhomme, N.; Seguin, L.; Rosseau, B.; Plantefol, M. 5-Hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via a specific interaction with 5-hydroxytrypatime 1B/1D receptors Mol. Pharmacol. 1996, 50, 752-762 (Pubitemid 26347694)
41. Rouselle, J. C.; Massot, O.; Delepierre, M.; Zifa, E.; Rosseau, B.; Fillion, G. Isolation and characterization of an endogenous peptide form rat brain interacting specifically with the serotonergic 1B receptor subtypes J. Biol. Chem. 1996, 271, 726-735 (Pubitemid 26034920)
42. Bridges, T. M.; LeBois, E. P.; Hopkins, C. R.; Wood, M. R.; Jones, J. K.; Conn, P. J.; Lindsley, C. W. Antipsychotic potential of muscarinic allosteric modulation Drug News Perspect. 2010, 23, 229-240
43. Conn, P. J.; Jones, C.; Lindsley, C. W. Subtype selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders Trends Pharmacol. Sci. 2009, 30, 148-156
44. Conn, P. J.; Lindsley, C. W.; Jones, C. Allosteric modulation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia Trends Pharmacol. Sci. 2009, 30, 25-31
45. Aurelio, L.; Valant, C.; Figler, H.; Flynn, B. L.; Linden, J.; Sexton, P. M.; Christopoulos, A.; Scammells, P. J. 3- and 6-Substituted 2-amino-4,5,6,7-tetrahydrothieno[2,3- c ]pyridines as A1 adenosine receptor allosteric modulators and antagonists Bioorg. Med. Chem. 2009, 17, 7353-7361
46. Valant, C.; Aurelio, L.; Urmaliya, V. B.; White, P.; Scammells, P. J.; Sexton, P. M.; Christopoulos, A. Delineating the mode of action of adenosine A1 receptor allosteric modulators Mol. Pharmacol. 2010, 78, 444-455
47. Aurelio, L.; Valant, C.; Flynn, B. L.; Sexton, P. M.; Christopoulos, A.; Scammells, P. J. Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes J. Med. Chem. 2009, 52, 4543-4547
48. 3 adenosine receptor J. Med. Chem. 2009, 52, 2098-2108
49. 3 adenosine receptor Biochem. Pharmacol. 2010, 79, 48-56
50. Pihlavisto, M.; Sjöholm, B.; Scheinin, M.; Wurster, S. Modulation of agonist binding to recombinant human α2-adrenoceptors by sodium ions Biochim. Biophys. Acta 1998, 1448, 135-146 (Pubitemid 28526627)
51. Swaminath, G.; Steenhuis, J.; Kobilka, B.; Lee, T. W. Allosteric modulation of β2-adrenergic receptor by Zn(2+) Mol. Pharmacol. 2002, 61, 65-72 (Pubitemid 34049513)
52. Price, M. R.; Baillie, G. L.; Thomas, A.; Stevenson, L. A.; Easson, M.; Goodwin, R.; McLean, A.; McIntosh, L.; Goodwin, G.; Walker, G.; Westwood, P.; Marrs, J.; Thomson, F.; Cowley, P.; Christopoulos, A.; Pertwee, R. G.; Ross, R. A. Allosteric modulation of the cannabinoid CB1 receptor Mol. Pharmacol. 2005, 68, 1484-1495 (Pubitemid 41540004)
53. Horswill, J. G.; Bali, U.; Shaaban, S.; Keily, J. F.; Jeevaratnam, P.; Babbs, A. J.; Reynet, C.; Wong Kai In, P. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats Br. J. Pharmacol. 2007, 152, 805-814 (Pubitemid 350034966)
54. Navarro, H. A.; Howard, J. L.; Pollard, G. T.; Carroll, F. I. Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter Br. J. Pharmacol. 2009, 156, 1178-1184
55. Marsh, D. R.; Flemming, J. M. Inhibition of CXCR1 and CXCR2 chemokine receptors attenuates acute inflammation, preserves gray matter and diminishes autonomic dysreflexia after spinal cord injury Spinal Cord 2011, 49, 337-344
56. Sablone, M. R.; Cesta, M. C.; Moriconi, A.; Aramini, A.; Bizzarri, C.; Di Giacinto, C.; Di Bitondo, R.; Gloaguen, I.; Aschi, M.; Crucianelli, M.; Bertini, R.; Allegretti, M. Structure-activity relationship of novel phenylacetic CXCR1 inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 4026-4030
57. Varney, M. L.; Singh, S.; Li, A.; Mayer-Ezell, R.; Bond, R.; Singh, R. K. Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases Cancer Lett. 2011, 300, 180-188
58. Chapman, R. W.; Phillips, J. E.; Hipkin, R. W.; Curran, A. K.; Lundell, D.; Fine, J. S. CXCR2 antagonists for the treatment of pulmonary disease Pharmacol. Ther. 2009, 121, 55-68
59. Singh, S.; Sadanandam, A.; Nannuru, K. C.; Varney, M. L.; Mayer-Ezell, R.; Bond, R.; Singh, R. K. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis Clin. Cancer Res. 2009, 15, 2380-2386
60. Sachpatzidis, A.; Benton, B. K.; Manfredi, J. P.; Wang, H.; Hamilton, A.; Dohlman, H. G.; Lolis, E. Identification of allosteric peptide agonists of CXCR4 J. Biol. Chem. 2003, 278, 896-907 (Pubitemid 36790764)
61. Zhao, J.; Ben, L. H.; Wu, Y. L.; Hu, W.; Ling, K.; Xin, S. M.; Nie, H. L.; Ma, L.; Pei, G. Anti-HIV agent trichosanthin enhances the capabilities of chemokines to stimulate chemotaxis and G protein activation, and this is mediated through interaction of trichosanthin and chemokine receptors J. Exp. Med. 1999, 190, 101-111 (Pubitemid 29330127)
62. Cashen, A. F.; Nervi, B.; DiPersio, J. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent Future Oncol. 2007, 3, 19-27
63. Vaidehi, N.; Schlyer, S.; Trabanino, R. J.; Floriano, W. B.; Abrol, R.; Sharma, S.; Kochanny, M.; Koovakat, S.; Dunning, L.; Liang, M.; Fox, J. M.; de Mendonça, F. L.; Pease, J. E.; Goddard, W. A., III; Horuk, R. Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation J. Biol. Chem. 2006, 281, 27613-27620 (Pubitemid 44401786)
64. Gladue, R. P.; Cole, S. H.; Roach, M. L.; Tylaska, L. A.; Nelson, R. T.; Shepard, R. M.; McNeish, J. D.; Ogborne, K. T.; Neote, K. S. The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice J. Immunol. 2006, 176, 3141-3148
65. Sabroe, I.; Peck, M. J.; Van Keulen, B. J.; Jorritsma, A.; Simmons, G.; Clapham, P. R.; Williams, T. J.; Pease, J. E. A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry J. Biol. Chem. 2000, 275, 25985-25992
66. Watson, C.; Jenkinson, S.; Kazmierski, W.; Kenakin, T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor Mol. Pharmacol. 2005, 67, 1268-1282 (Pubitemid 40410427)
67. Nichols, W. G.; Steel, H. M.; Bonny, T.; Adkison, K.; Curtis, L.; Millard, J.; Kabeya, K.; Clumeck, N. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140) Antimicrob. Agents Chemother. 2008, 52, 858-865 (Pubitemid 351358363)
68. Maeda, K.; Nakata, H.; Koh, Y.; Miyakawa, T.; Ogata, H.; Takaoka, Y.; Shibayama, S.; Sagawa, K.; Fukushima, D.; Moravek, J.; Koyanagi, Y.; Mitsuya, H. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro J. Virol. 2004, 78, 8654-8662 (Pubitemid 39025131)
69. Tremblay, C. L.; Giguel, F.; Guan, Y.; Chou, T. C.; Takashima, K.; Hirsch, M. S. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro Antimicrob. Agents Chemother. 2005, 49, 3483-3485 (Pubitemid 41060599)
70. Strizki, J. M.; Xu, S.; Wagner, N. E.; Wojcik, L.; Liu, J.; Hou, Y.; Endres, M.; Palani, A.; Shapiro, S.; Clader, J. W.; Greenlee, W. J.; Tagat, J. R.; McCombie, S.; Cox, K.; Fawzi, A. B.; Chou, C. C.; Pugliese-Sivo, C.; Davies, L.; Moreno, M. E.; Ho, D. D.; Trkola, A.; Stoddart, C. A.; Moore, J. P.; Reyes, G. R.; Baroudy, B. M. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 12718-12723 (Pubitemid 33020012)
71. Klibanov, O. M. Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection Curr. Opin. Invest. Drugs 2009, 10, 845-859
72. Meanwell, N. A.; Kadow, J. F. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS Curr. Opin. Invest. Drugs 2007, 8, 669-681 (Pubitemid 47205251)
73. Schetz, J. A.; Sibley, D. R. Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors J. Neurochem. 1997, 68, 1990-1997 (Pubitemid 27176135)
74. Hoare, S. R.; Coldwell, M. C.; Armstrong, D.; Strange, P. G. Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues Br. J. Pharmacol. 2000, 130, 1045-1059 (Pubitemid 30453539)
75. De Mey, J. G.; Compeer, M. G.; Lemkens, P.; Meens, M. J. ET(A)-receptor antagonists or allosteric modulators? Trends Pharamcol. Sci. 2011, 32, 345-351
76. Heitman, L. H.; Ye, K.; Oosterom, J.; Ijzerman, A. P. Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor Mol. Pharmacol. 2008, 73, 1808-1815 (Pubitemid 351724368)
77. Holst, B.; Frimurer, T. M.; Mokrosinski, J.; Halkjaer, T.; Cullberg, K. B.; Underwood, C. R.; Schwartz, T. W. Overlapping binding site for the endogenous agonist, small-molecule agonists, and ago-allosteric modulators on the ghrelin receptor Mol. Pharmacol. 2009, 75, 44-59
78. Janovick, J. A.; Maya-Núñez, G.; Ulloa-Aguirre, A.; Huhtaniemi, I. T.; Dias, J. A.; Verbost, P.; Conn, P. M. Increased plasma membrane expression of human follicle-stimulating hormone receptor by a small molecule thienopyr(im)idine Mol. Cell. Endocrinol. 2009, 298, 84-88
79. 3H]Org 43553, the first low-molecular-weight agonistic and allosteric radioligand for the human luteinizing hormone receptor Mol. Pharmacol. 2008, 73, 518-524 (Pubitemid 351159222)
80. Gregory, K. J.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of muscarinic acetylcholine receptors Curr. Neuropharmacol. 2007, 5, 157-167 (Pubitemid 351863857)
81. Jones, C. K.; Brady, A. E.; Davis, A. A.; Xiang, Z.; Bubser, M.; Tantawy, M. N.; Kane, A.; Bridges, T. M.; Kennedy, J. P.; Bradley, S. R.; Peterson, T.; Baldwin, R. M.; Kessler, R.; Deutch, A.; Lah, J. L.; Levey, A. I.; Lindsley, C. W.; Conn, P. J. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor reduces amyloid processing and produces antipsychotic-like activity in rats J. Neurosci. 2008, 28 (41) 10422-10433
82. Marlo, J. E.; Niswender, C. M.; Luo, Q.; Brady, A. E.; Shirey, J. K.; Rodriguez, A. L.; Bridges, T. M.; Williams, R.; Days, E.; Nalywajko, N. T.; Austin, C.; Williams, M.; Xiang, Y.; Orton, D.; Brown, H. A.; Kim, K.; Lindsley, C. W.; Weaver, C. D.; Conn, P. J. Identification and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity Mol. Pharmacol. 2009, 75, 577-588
83. Reid, P. R.; Bridges, T. M.; Sheffler, D. J.; Cho, H. P.; Lewis, L. M.; Days, E.; Daniels, J. S.; Jones, C. K.; Niswender, C. M.; Weaver, C. D.; Conn, P. J.; Lindsley, C. W.; Wood, M. R. Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe Bioorg. Med. Chem. Lett. 2011, 21, 2697-2701
84. 1 PAM Bioorg. Med. Chem. Lett. 2010, 20, 1972-1975
85. Lebois, E. P.; Bridges, T. M.; Dawson, E. S.; Kennedy, J. p.; Xiang, Z.; Jadhav, S. B.; Yin, H.; Meiler, J.; Jones, C. K.; Conn, P. J.; Weaver, C. D.; Lindsley, C. W. Discovery and development of novel subtype-selective M1 allosteric agonists for the investigation of M1 receptor function ACS Chem. Neurosci. 2010, 1, 104-121
86. Suga, H.; Ehlert, F. J. Investigating the interaction of McN-A-343 with the M2 muscarinic receptor using its nitrogen mustard derivative Biochem. Pharmacol. 2010, 79, 1025-1035
87. Maier-Peuschel, M.; Frölich, N.; Dees, C.; Hommers, L. G.; Hoffmann, C.; Nikolaev, V. O.; Lohse, M. J. A fluorescence resonance energy transfer-based M2 muscarinic receptor sensor reveals rapid kinetics of allosteric modulation J. Biol. Chem. 2010, 285, 8793-8800
88. May, L. T.; Avlani, V. A.; Langmead, C. J.; Herdon, H. J.; Wood, M. D.; Sexton, P. M.; Christopoulos, A. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors Mol. Pharmacol. 2007, 72, 463-476 (Pubitemid 47124126)
89. 4 muscarinic acetylcholine receptors Mol. Pharmacol. 2006, 70, 736-746 (Pubitemid 44092334)
90. 4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties Neuropsychopharmacology 2010, 35, 855-869
91. Shirey, J. K.; Xiang, Z.; Orton, D.; Brady, A. E.; Johnson, K. A.; Williams, R.; Ayala, J. E.; Rodriguez, A. L.; Wess, J.; Weaver, D; Niswender, C. M.; Conn, P. J. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission Nat. Chem. Biol. 2008, 4, 42-50 (Pubitemid 350273654)
92. Brady, A.; Jones, C. K.; Bridges, T. M.; Kennedy, P. J.; Thompson, A. D.; Breininger, M. L.; Gentry, P. R.; Yin, H.; Jadhav, S. B.; Shirey, J.; Conn, P. J.; Lindsley, C. W. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotion behavior in rats J. Pharmacol. Exp. Ther. 2008, 327, 941-953
93. 4 muscarinic acetylcholine receptor ChemMedChem 2009, 4, 1600-1607
94. Bridges, T. M.; Marlo, J. E.; Niswender, C. M.; Jones, J. K.; Jadhav, S. B.; Gentry, P. R.; Weaver, C. D.; Conn, P. J.; Lindsley, C. W. Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N -benzyl isatins J. Med. Chem. 2009, 52, 3445-3448
95. 5 PAM Bioorg. Med. Chem. Lett. 2010, 20, 558-562
96. Bridges, T. M.; Kennedy, J. P.; Hopkins, C. R.; Conn, P. J.; Lindsley, C. W. Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators Bioorg. Med. Chem. Lett. 2010, 20, 5617-5622
97. Kathmann, M.; Flau, K.; Redmer, A.; Tränkle, C.; Schlicker, E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors Naunyn Schmiedeberg's Arch. Pharmacol. 2006, 372, 354-361
98. Thomas, E. A.; Carson, M. J.; Neal, M. J.; Sutcliffe, J. G. Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 14115-14119 (Pubitemid 28009719)
99. Im, W. B.; Chio, C. L.; Alberts, G. L.; Dinh, D. M. Positive allosteric modulator of the human 5-HT2C receptor Mol. Pharmacol. 2003, 64, 78-84 (Pubitemid 36759820)
100. Hoare, S. R.; Fleck, B. A.; Gross, R. S.; Crowe, P. D.; Williams, J. P.; Grigoriadis, D. E. Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation Mol. Pharmacol. 2008, 73, 1371-1380 (Pubitemid 351574827)
101. Hoare, S. R.; Brown, B. T.; Santos, M. A.; Malany, S.; Betz, S. F.; Grigoriadis, D. E. Single amino acid residue determinants of non-peptide antagonist binding to the corticotropin-releasing factor 1 (CRF1) receptor Biochem. Pharmacol. 2006, 72, 244-255 (Pubitemid 43850430)
102. Hoare, S. R.; Sullivan, S. K.; Ling, N.; Crowe, P. D.; Grigoriadis, D. E. Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists Mol. Pharmacol. 2003, 63, 751-765 (Pubitemid 36297349)
103. Gully, D.; Geslin, M.; Serva, L.; Fontaine, E.; Roger, P.; Lair, C.; Darre, V.; Marcy, C.; Rouby, P. E.; Simiand, J.; Guitard, J.; Gout, G.; Steinberg, R.; Rodier, D.; Griebel, G.; Soubrié, P.; Pascal, M.; Pruss, R.; Scatton, B.; Maffrand, J. P.; Le Fur, G. 4-(2-Chloro-4-methoxy-5- methylphenyl)- N -[(1 S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5- methyl- N -(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization J. Pharmacol. Exp. Ther. 2002, 301, 322-332 (Pubitemid 34250311)
104. Griebel, G.; Simiand, J.; Steinberg, R.; Jung, M.; Gully, D.; Roger, P.; Geslin, M.; Scatton, B.; Maffrand, J. P.; Soubrié, P. 4-(2-Chloro-4-methoxy-5-methylphenyl)- N -[(1 S)-2-cyclopropyl-1-(3-fluoro-4- methylphenyl)ethyl]5-methyl- N -(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders J. Pharmacol. Exp. Ther. 2002, 301, 333-345 (Pubitemid 34250312)
105. Hoare, S. R. Allosteric modulators of class B G-protein-coupled receptors Curr. Neuropharmacol. 2007, 5, 168-179 (Pubitemid 351863858)
106. Chen, C.; Wilcoxen, K. M.; Huang, C. Q.; Xie, Y. F.; McCarthy, J. R.; Webb, T. R.; Zhu, Y. F.; Saunders, J.; Liu, X. J.; Chen, T. K.; Bozigian, H.; Grigoriadis, D. E. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7- dipropylaminopyrazolo[1,5- a ]pyrimidine (NBI 30775/R121919) and structure-activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists J. Med. Chem. 2004, 47, 4787-4798 (Pubitemid 39195568)
107. Salvatore, C. A.; Mallee, J. J.; Bell, I. M.; Zartman, C. B.; Williams, T. M.; Koblan, K. S.; Kane, S. A. Identification and pharmacological characterization of domains involved in binding of CGRP receptor antagonists to the calcitonin-like receptor Biochemistry 2006, 45, 1881-1887 (Pubitemid 43222131)
108. Petersen, K. F.; Sullivan, J. T. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans Diabetologia 2001, 44, 2018-2024 (Pubitemid 33124047)
109. Latsis, T.; Andersen, B.; Agius, L. Diverse effects of two allosteric inhibitors on the phosphorylation state of glycogen phosphorylase in hepatocytes Biochem. J. 2002, 368, 309-316 (Pubitemid 35463434)
110. Koole, C.; Wootten, D.; Simms, J.; Valant, C.; Sridhar, R.; Woodman, O. L.; Miller, L. J.; Summers, R. J.; Christopoulos, A.; Sexton, P. M. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening Mol. Pharmacol. 2010, 78, 456-465
111. Koole, C.; Wootten, D.; Simms, J.; Valant, C.; Miller, L. J.; Christopoulos, A.; Sexton, P. M. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation Mol. Pharmacol. 2011, 80, 486-497
112. Nemeth, E. F.; Steffey, M. E.; Hammerland, L. G.; Hung, B. C.; Van Wagenen, B. C.; DelMar, E. G.; Balandrin, M. F. Calcimimetics with potent and selective activity on the parathyroid calcium receptor Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4040-4045 (Pubitemid 28173250)
113. Zhang, Z.; Qiu, W.; Quinn, S. J.; Conigrave, A. D.; Brown, E. M.; Bai, M. Three adjacent serines in the extracellular domains of the CaR are required for l -amino acid-mediated potentiation of receptor function J. Biol. Chem. 2002, 277, 33727-33735
114. Zhang, Z.; Jiang, Y.; Quinn, S. J.; Krapcho, K.; Nemeth, E. F.; Bai, M. l -Phenylalanine and NPS R-467 synergistically potentiate the function of the extracellular calcium-sensing receptor through distinct sites J. Biol. Chem. 2002, 277, 33736-33741
115. Nemeth, E. F.; Heaton, W. H.; Miller, M.; Fox, J.; Balandrin, M. F.; Van Wagenen, B. C.; Colloton, M.; Karbon, W.; Scherrer, J.; Shatzen, E.; Rishton, G.; Scully, S.; Qi, M.; Harris, R.; Lacey, D.; Martin, D. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl J. Pharmacol. Exp. Ther. 2004, 308, 627-635 (Pubitemid 38134225)
116. 2+ receptor antagonists that stimulate secretion of parathyroid hormone J. Pharmacol. Exp. Ther. 2001, 299, 323-331 (Pubitemid 32905150)
117. Kessler, A.; Faure, H.; Petrel, C.; Rognan, D.; Césario, M.; Ruat, M.; Dauban, P.; Dodd, R. H. N 1-Benzoyl- N 2-[1-(1-naphthyl)ethyl]- trans -1,2-diaminocyclohexanes: development of 4-chlorophenylcarboxamide (calhex 231) as a new calcium sensing receptor ligand demonstrating potent calcilytic activity J. Med. Chem. 2006, 49, 5119-5128 (Pubitemid 44260208)
118. Kumar, S.; Matheny, C. J.; Hoffman, S. J.; Marquis, R. W.; Schultz, M.; Liang, X.; Vasko, J. A.; Stroup, G. B.; Vaden, V. R.; Haley, H.; Fox, J.; DelMar, E. G.; Nemeth, E. F.; Lago, A. M.; Callahan, J. F.; Bhatnagar, P.; Huffman, W. F.; Gowen, M.; Yi, B.; Danoff, T. M.; Fitzpatrick, L. A. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation Bone 2010, 46, 534-542
119. Marquis, R. W.; Lago, A. M.; Callahan, J. F.; Rahman, A.; Dong, X.; Stroup, G. B.; Hoffman, S.; Gowen, M.; DelMar, E. G.; Van Wagenen, B. C.; Logan, S.; Shimizu, S.; Fox, J.; Nemeth, E. F.; Roethke, T.; Smith, B. R.; Ward, K. W.; Bhatnagar, P. Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues J. Med. Chem. 2009, 52, 6599-6605
120. Guery, S.; Floersheim, P.; Kaupmann, K.; Froestl, W. Syntheses and optimization of new GS39783 analogues as positive allosteric modulators of GABA B receptors Bioorg. Med. Chem. Lett. 2007, 17, 6206-6211 (Pubitemid 47552827)
121. Malherbe, P.; Masciadri, R.; Norcross, R. D.; Knoflach, F.; Kratzeisen, C.; Zenner, M. T.; Kolb, Y.; Marcuz, A.; Huwyler, J.; Nakagawa, T.; Porter, R. H.; Thomas, A. W.; Wettstein, J. G.; Sleight, A. J.; Spooren, W.; Prinssen, E. P. Characterization of (R, S)-5,7-di- tert -butyl-3-hydroxy-3-trifluoromethyl-3 H -benzofuran-2-one as a positive allosteric modulator of GABA B receptors Br. J. Pharmacol. 2008, 154, 797-811 (Pubitemid 351821586)
122. Urwyler, S.; Mosbacher, J.; Lingenhoehl, K.; Heid, J.; Hofstetter, K.; Froestl, W.; Bettler, B.; Kaupmann, K. Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-di- tert -butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501 Mol. Pharmacol. 2001, 60, 963-971 (Pubitemid 33027431)
123. Jacobson, L. H.; Cryan, J. F. Evaluation of the anxiolytic-like profile of the GABA B receptor positive modulator CGP7930 in rodents Neuropharmacology 2008, 54, 854-862
124. Brusberg, M.; Ravnefjord, A.; Martinsson, R.; Larsson, H.; Martinez, V.; Lindström, E. The GABA(B) receptor agonist, baclofen, and the positive allosteric modulator, CGP7930, inhibit visceral pain-related responses to colorectal distension in rats Neuropharmacology 2009, 56, 362-367
125. Urwyler, S.; Pozza, M. F.; Lingenhoehl, K; Mosbacher, J.; Lampert, C.;
126. Litschig, S.; Gasparini, F.; Rueegg, D.; Stoehr, N.; Flor, P. J.; Vranesic, I.; Prézeau, L.; Pin, J. P.; Thomsen, C.; Kuhn, R. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding Mol. Pharmacol. 1999, 55, 453-461 (Pubitemid 29128101)
127. Carroll, F. Y.; Stolle, A.; Beart, P. M.; Voerste, A.; Brabet, I.; Mauler, F.; Joly, C.; Antonicek, H.; Bockaert, J.; Müller, T.; Pin, J. P.; Prézeau, L. BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity Mol. Pharmacol. 2001, 59, 965-973 (Pubitemid 32381574)
128. 3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists Mol. Pharmacol. 2003, 63, 1082-1093 (Pubitemid 36529927)
129. Malherbe, P.; Kratochwil, N.; Knoflach, F.; Zenner, M. T.; Kew, J. N.; Kratzeisen, C.; Maerki, H. P.; Adam, G.; Mutel, V. Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor J. Biol. Chem. 2003, 278, 8340-8347 (Pubitemid 36800582)
130. Lavreysen, H.; Wouters, R.; Bischoff, F.; Nóbrega Pereira, S.; Langlois, X.; Blokland, S.; Somers, M.; Dillen, L.; Lesage, A. S. JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist Neurpharmacology 2004, 47, 961-972 (Pubitemid 39535837)
131. Kohara, A.; Toya, T.; Tamura, S.; Watabiki, T.; Nagakura, Y.; Shitaka, Y.; Hayashibe, S.; Kawabata, S.; Okada, M. Radioligand binding properties and pharmacological characterization of 6-amino- N -cyclohexyl- N,3- dimethylthiazolo[3,2- a ]benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1 J. Pharmacol. Exp. Ther. 2005, 315, 163-169 (Pubitemid 41380509)
132. El-Kouhen, O.; Lehto, S. G.; Pan, J. B.; Chang, R.; Baker, S. J.; Zhong, C.; Hollingsworth, P. R.; Mikusa, J. P.; Cronin, E. A.; Chu, K. L.; McGaraughty, S. P.; Uchic, M. E.; Miller, L. N.; Rodell, N. M.; Patel, M.; Bhatia, P.; Mezler, M.; Kolasa, T.; Zheng, G. Z.; Fox, G. B.; Stewart, A. O.; Decker, M. W.; Moreland, R. B.; Brioni, J. D.; Honore, P. Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist Br. J. Pharmacol. 2006, 149, 761-774 (Pubitemid 44748069)
133. Suzuki, G.; Kimura, T.; Satow, A.; Kaneko, N.; Fukuda, J.; Hikichi, H.; Sakai, N.; Maehara, S.; Kawagoe-Takaki, H.; Hata, M.; Azuma, T.; Ito, S.; Kawamoto, H.; Ohta, H. Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1 H -1,2,3-triazol-4-yl]- N -isopropyl- N -methyl-3,6-dihydropyridine-1(2 H)-carboxamide (FTIDC) J. Pharmacol. Exp. Ther. 2007, 321, 1144-1153 (Pubitemid 46766521)
134. Kohara, A.; Nagakura, Y.; Kiso, T.; Toya, T.; Watabiki, T.; Tamura, S.; Shitaka, Y.; Itahana, H.; Okada, M. Antinociceptive profile of a selective metabotropic glutamate receptor 1 antagonist YM-230888 in chronic pain rodent models Eur. J. Pharmacol. 2007, 571, 8-16 (Pubitemid 47284045)
135. Fukuda, J.; Suzuki, G.; Kimura, T.; Nagatomi, Y.; Ito, S.; Kawamoto, H.; Ozaki, S.; Ohta, H. Identification of a novel transmembrane domain involved in the negative modulation of mGluR1 using a newly discovered allosteric mGluR1 antagonist, 3-cyclohexyl-5-fluoro-6-methyl-7-(2-morpholin-4-ylethoxy)-4 H -chromen-4-one Neuropharmacology 2009, 57, 438-445
136. Hemstapat, K.; de Paulis, T.; Chen, Y.; Brady, A. E.; Grover, V. K.; Alagille, D.; Tamagnan, G. D.; Conn, P. J. A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators Mol. Pharmacol. 2006, 70, 616-626 (Pubitemid 44092322)
137. Knoflach, F.; Mutel, V.; Jolidon, S.; Kew, J. N.; Malherbe, P.; Vieira, E.; Wichmann, J.; Kemp, J. A. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 13402-13407 (Pubitemid 33051375)
138. Vieira, E.; Huwyler, J.; Jolidon, S.; Knoflach, F.; Mutel, V.; Wichmann, J. Fluorinated 9 H -xanthene-9-carboxylic acid oxazol-2-yl-amides as potent, orally available mGlu1 receptor enhancers Bioorg. Med. Chem. Lett. 2009, 19, 1666-1669
139. 1) ACS Chem. Neurosci. 2011, 2, 394-401
140. Johnson, M. P.; Baez, M.; Jagdmann, G. E., Jr.; Britton, T. C.; Large, T. H.; Callagaro, D. O.; Tizzano, J. P.; Monn, J. A.; Schoepp, D. D. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N -(4-(2-methoxyphenoxy)phenyl)- N -(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine J. Med. Chem. 2003, 46, 3189-3192 (Pubitemid 36842403)
141. Johnson, M. P.; Barda, D.; Britton, T. C.; Emkey, R.; Hornback, W. J.; Jagdmann, G. E.; McKinzie, D. L.; Nisenbaum, E. S.; Tizzano, J. P.; Schoepp, D. D. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s) Psychopharmacology (Berlin) 2005, 179, 271-283 (Pubitemid 40576715)
142. Barda, D. A.; Wang, Z. Q.; Britton, T. C.; Henry, S. S.; Jagdmann, G. E.; Coleman, D. S.; Johnson, M. P.; Andis, S. L.; Schoepp, D. D. SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N -(4-phenoxyphenyl)- N -(3-pyridinylmethyl)ethanesulfonamide Bioorg. Med. Chem. Lett. 2004, 14, 3099-3102 (Pubitemid 38624570)
143. Galici, R.; Echemendia, N. G.; Rodriguez, A. L.; Conn, P. J. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity J. Pharmacol. Exp. Ther. 2005, 315, 1181-1187 (Pubitemid 41635406)
144. Galici, R.; Jones, C. K.; Hemstapat, K.; Nong, Y.; Echemendia, N. G.; Williams, L. C.; de Paulis, T.; Conn, P. J. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice J. Pharmacol. Exp. Ther. 2006, 318, 173-185
145. D'Alessandro, P. L.; Corti, C.; Roth, A.; Ugolini, A.; Sava, A.; Montanari, D.; Bianchi, F.; Garland, S. L.; Powney, B.; Koppe, E. L.; Rocheville, M.; Osborne, G.; Perez, P.; de la Fuente, J.; De Los Frailes, M.; Smith, P. W.; Branch, C.; Nash, D.; Watson, S. P. The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2 Bioorg. Med. Chem. Lett. 2010, 20, 759-762
146. Hemstapat, K.; Da Costa, H.; Nong, Y.; Brady, A. E.; Luo, Q.; Niswender, C. M.; Tamagnan, G. D.; Conn, P. J. A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors J. Pharmacol. Exp. Ther. 2007, 322, 254-264 (Pubitemid 46956377)
147. Woltering, T. J.; Adam, G.; Alanine, A.; Wichmann, J.; Knoflach, F.; Mutel, V.; Gatti, S. Synthesis and characterization of 8-ethynyl-1,3-dihydro- benzo[ b ][1,4]diazepin-2-one derivatives: new potent non-competitive metabotropic glutamate receptor 2/3 antagonists. Part 1 Bioorg. Med. Chem. Lett. 2007, 17, 6811-6815 (Pubitemid 350061305)
148. Sheffler, D. J.; Pinkerton, A. B.; Dahl, R.; Markou, A.; Cosford, N. D. P. Recent progress in the synthesis and characterization of group II metabotropic glutamate receptor allosteric modulators ACS Chem. Neurosci. 2011, 2, 382-393
149. Maj, M.; Bruno, V.; Dragic, Z.; Yamamoto, R.; Battaglia, G.; Inderbitzin, W.; Stoehr, N.; Stein, T.; Gasparini, F.; Vranesic, I.; Kuhn, R.; Nicoletti, F.; Flor, P. J. (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection Neropharmacology 2003, 45, 895-906 (Pubitemid 37297915)
150. Marino, M. J.; Williams, D. L., Jr; O'Brien, J. A.; Valenti, O.; McDonald, T. P.; Clements, M. K.; Wang, R.; DiLella, A. G.; Hess, J. F.; Kinney, G. G.; Conn, P. J. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13668-13673 (Pubitemid 37444797)
151. Engers, D. W.; Niswender, C. M.; Weaver, C. D.; Jadhav, S.; Menon, U. N.; Zamorano, R.; Conn, P. J.; Lindsley, C. W.; Hopkins, C. R. Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs) J. Med. Chem. 2009, 52, 4115-4118
152. Niswender, C. M.; Johnson, K. A.; Weaver, C. D.; Jones, C. K.; Xiang, Z.; Luo, Q.; Rodriguez, A. L.; Marlo, J. E.; de Paulis, T.; Thompson, A. D.; Days, E. L.; Nalywajko, T.; Austin, C. A.; Williams, M. B.; Ayala, J. E.; Williams, R.; Lindsley, C. W.; Conn, P. J. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4 Mol. Pharmacol. 2008, 74, 1345-1358
153. Williams, R.; Johnson, K. A.; Gentry, P. R.; Niswender, C. M.; Weaver, C. D.; Conn, P. J.; Lindsley, C. W.; Hopkins, C. R. Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4) Bioorg. Med. Chem. Lett. 2009, 19, 4967-4970
154. Williams, R.; Niswender, C. M.; Luo, Q.; Le, U.; Conn, P. J.; Lindsley, C. W. Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead Bioorg. Med. Chem. Lett. 2009, 19, 962-966
155. Williams, R.; Zhou, Y.; Niswender, C. M.; Luo, Q.; Conn, P. J.; Lindsley, C. W.; Hopkins, C. R. Re-exploration of the PHCCC scaffold: discovery of improved positive allosteric modulators of mGluR4 ACS Chem. Neurosci. 2010, 1, 411-419
156. Mathiesen, J. M.; Svendsen, N.; Bräuner-Osborne, H.; Thomsen, C.; Ramirez, M. T. Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP Br. J. Pharmacol. 2003, 138, 1026-1030 (Pubitemid 36459824)
157. Robichaud, A. J.; Engers, D. W.; Lindsley, C. W.; Hopkins, C. R. Recent progress in the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics ACS Chem. Neurosci. 2011, 2, 433-449
158. Cosford, N. D.; Tehrani, L.; Roppe, J.; Schweiger, E.; Smith, N. D.; Anderson, J.; Bristow, L.; Brodkin, J.; Jiang, X.; McDonald, I.; Rao, S.; Washburn, M.; Varney, M. A. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity J. Med. Chem. 2003, 46, 204-206 (Pubitemid 36078139)
159. Porter, R. H.; Jaeschke, G.; Spooren, W.; Ballard, T. M.; Büttelmann, B.; Kolczewski, S.; Peters, J. U.; Prinssen, E.; Wichmann, J.; Vieira, E.; Mühlemann, A.; Gatti, S.; Mutel, V.; Malherbe, P. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity J. Pharmacol. Exp. Ther. 2005, 315, 711-721 (Pubitemid 41500737)
160. Rodriguez, A. L.; Grier, M. D.; Jones, C. K.; Herman, E. J.; Kane, A. S.; Smith, R. L.; Williams, R.; Zhou, Y.; Marlo, J. E.; Days, E. L.; Blatt, T. N.; Jadhav, S.; Menon, U. N.; Vinson, P. N.; Rook, J. M.; Stauffer, S. R.; Niswender, C. M.; Lindsley, C. W.; Weaver, C. D.; Conn, P. J. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity Mol. Pharmacol. 2010, 78, 1105-1123
161. O'Brien, J. A.; Lemaire, W.; Chen, T. B.; Chang, R. S.; Jacobson, M. A.; Ha, S. N.; Lindsley, C. W.; Schaffhauser, H. J.; Sur, C.; Pettibone, D. J.; Conn, P. J.; Williams, D. L., Jr. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 Mol. Pharmacol. 2003, 64, 731-740 (Pubitemid 37048578)
162. Hammond, A. S.; Rodriguez, A. L.; Townsend, S. D.; Niswender, C. M.; Gregory, K. J.; Lindsley, C. W.; Conn, P. J. Discovery of a novel chemical class of mGlu(5) allosteric ligands with distinct modes of pharmacology ACS Chem. Neurosci. 2010, 1, 702-716
163. Zhao, Z.; Wisnoski, D. D.; O'Brien, J. A.; Lemaire, W.; Williams, D. L., Jr.; Jacobson, M. A.; Wittman, M.; Ha, S. N.; Schaffhauser, H.; Sur, C.; Pettibone, D. J.; Duggan, M. E.; Conn, P. J.; Hartman, G. D.; Lindsley, C. W. Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA Bioorg. Med. Chem. Lett. 2007, 17, 1386-1391 (Pubitemid 46240838)
164. O'Brien, J. A.; Lemaire, W.; Wittmann, M.; Jacobson, M. A.; Ha, S. N.; Wisnoski, D. D.; Lindsley, C. W.; Schaffhauser, H. J.; Sur, C.; Duggan, M. E.; Pettibone, D. J.; Conn, J.; Williams, D. L. A novel selective allosteric modulator potentiates the activity of the native metabotropic glutamate receptor subtype 5 (mGluR5) in rat forebrain J. Pharmacol. Exp. Ther. 2004, 309 (2) 568-579
165. Kinney, G. G.; O'Brien, J. A.; Lemaire, W.; Burno, M.; Bickel, D. J.; Clements, M. K.; Chen, T. B.; Wisnoski, D. D.; Lindsley, C. W.; Tiller, P. R.; Smith, S.; Jacobson, M. A.; Sur, C.; Duggan, M. E.; Pettibone, D. J.; Conn, P. J.; Williams, D. L., Jr. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models J. Pharmacol. Exp. Ther. 2005, 313, 199-206 (Pubitemid 40411343)
166. Lindsley, C. W.; Wisnoski, D. D.; Leister, W. H.; O'Brien, J. A.; Lemaire, W.; Williams, D. L., Jr.; Burno, M.; Sur, C.; Kinney, G. G.; Pettibone, D. J.; Tiller, P. R.; Smith, S.; Duggan, M. E.; Hartman, G. D.; Conn, P. J.; Huff, J. R. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N -(1,3-diphenyl-1 H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo J. Med. Chem. 2004, 47, 5825-5828 (Pubitemid 39507327)
167. de Paulis, T.; Hemstapat, K.; Chen, Y.; Zhang, Y.; Saleh, S.; Alagille, D.; Baldwin, R. M.; Tamagnan, G. D.; Conn, P. J. Substituent effects of N -(1,3-diphenyl-1 H -pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes J. Med. Chem. 2006, 49, 3332-3344 (Pubitemid 43830531)
168. Liu, F.; Grauer, S.; Kelley, C.; Navarra, R.; Graf, R.; Zhang, G.; Atkinson, P. J.; Popiolek, M.; Wantuch, C.; Khawaja, X.; Smith, D.; Olsen, M.; Kouranova, E.; Lai, M.; Pruthi, F.; Pulicicchio, C.; Day, M.; Gilbert, A.; Pausch, M. H.; Brandon, N. J.; Beyer, C. E.; Comery, T. A.; Logue, S.; Rosenzweig-Lipson, S.; Marquis, K. L. ADX47273 [ S -(4-fluoro-phenyl)-{3-[3-(4- fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities J. Pharmacol. Exp. Ther. 2008, 327, 827-839
169. Engers, D. W.; Rodriguez, A. L.; Oluwatola, O.; Hammond, A. S.; Venable, D. F.; Williams, R.; Sulikowski, G. A.; Conn, P. J.; Lindsley, C. W. Synthesis, SAR and unanticipated pharmacological profiles of analogs of the mGluR5 ago-potentitaor ADX-47273 ChemMedChem 2009, 4, 505-511
170. 5 ACS Chem. Neurosci. 2011, 2, 411-432
171. 5) ACS Chem. Neurosci. 2011, 2, 450-470
172. Mitsukawa, K.; Yamamoto, R.; Ofner, S.; Nozulak, J.; Pescott, O.; Lukic, S.; Stoehr, N.; Mombereau, C.; Kuhn, R.; McAllister, K. H.; van der Putten, H.; Cryan, J. F.; Flor, P. J. A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 18712-18717 (Pubitemid 43011291)
173. Suzuki, G.; Tsukamoto, N.; Fushiki, H.; Kawagishi, A.; Nakamura, M.; Kurihara, H.; Mitsuya, M.; Ohkubo, M.; Ohta, H. In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists J. Pharmacol. Exp. Ther. 2007, 323, 147-156 (Pubitemid 47443271)
174. Li, X.; Staszewski, L.; Xu, H.; Durik, K.; Zoller, M.; Adler, E. Human receptors for sweet and umani taste Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 4692-4696 (Pubitemid 34286046)
175. Nelson, G.; Chandrashekar, J.; Hoon, M. A.; Feng, L.; Zhao, G.; Ryba, N. J.; Zuker, C. S. An amino acid taste receptor Nature 2002, 416, 199-203
176. Zhang, F.; Klebansky, B.; Fine, R. M.; Liu, H.; Xu, H.; Servant, G.; Zoller, M.; Tachdijian, C.; Li, X. Molecular mechanism for the umani taste synergism Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 20930-20934
177. Zhang, F.; Klebansky, B.; Fine, R. M.; Liu, H.; Xu, H.; Servant, G.; Zoller, M.; Tachdjian, C.; Li, X. Molecular mechanism of the sweet taste enhancers Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 4752-4757
178. Servant, G.; Tachdjian, C.; Tang, X. Q.; Werner, S.; Zhang, F.; Li, X.; Kamdar, P.; Petrovic, G.; Ditschun, T.; Java, A. Positive allosteric modulators of the human sweet taste receptor enhance sweet taste Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 4746-4751
179. Xu, H.; Staszewski, L.; Tang, H.; Adler, E.; Zoller, M.; Li, X. Different functional roles of T1R subunits in the heterotrimeris taste receptors Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 14258-14263 (Pubitemid 39305062)
180. Jiang, P.; Cui, M.; Zhoa, B.; Snyder, L. A.; Benard, L. M.; Osman, R.; Margolskee, R. F.; Max, M. Identification of the cyclamate interaction site within the transmembrane domains of human sweet taste receptor subunit T1R3 J. Biol. Chem. 2005, 280, 34296-34305 (Pubitemid 41443155)
181. Valant, C.; Gregory, K. J.; Hall, N. E.; Scammells, P. J.; Lew, M. J.; Sexton, P. M.; Christopoulos, A. A novel mechanism of G protein-coupled receptor functional selectivity: muscarinic partial agonist McN-A-343 as a bitopic orhtosteric/allosteric ligand J. Biol. Chem. 2008, 283, 29312-29321
182. Valant, C.; Sexton, P. M.; Christopoulos, A. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs Mol. Int. 2009, 9, 125-135
183. 1 muscarinic acetylcholine Mol. Pharmacol. 2010, 78, 94-104
184. Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric modulators of GPCRs: taking advantage of permissive receptor pharmacology Trends Pharmacol. Sci. 2007, 28, 382-389 (Pubitemid 47087967)
185. Digby, G. J.; Conn, P. J.; Lindsley, C. W. Orthosteric- and allosteric-induced ligand-directed trafficking at G protein-coupled receptors Curr. Opin. Drug Discovery Dev. 2010, 13, 577-586
186. Urban, J. D.; Clarke, W. P.; von Zastrow, M.; Nichols, D. E.; Kobilla, B.; Weinstein, H.; Javitch, J. A.; Roth, B. L.; Christopolous, A.; Sexton, P. M.; Miller, K. J.; Spedding, M.; Mailman, R. B. Functional selectivity and classical concepts of quantitative pharmacology J. Pharmacol. Exp. Ther. 2007, 320, 1-13 (Pubitemid 46025713)
187. Mathiesen, J. M.; Ulven, T.; Martini, L.; Gerlach, L. O.; Heinemann, A.; Kostenis, E. Identification of indole derivatives exclusively interfering with a G protein independent signaling pathway of the prostaglandin D2 receptor CRTH2 Mol. Pharmacol. 2005, 68, 393-402 (Pubitemid 41058303)
188. Zhang, Y.; Rodriguez, A. L.; Conn, P. J. Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes J. Pharmacol. Exp. Ther. 2005, 315, 1212-1219 (Pubitemid 41635410)
189. Smith, N. J.; Milligan, G. Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes Pharmacol. Rev. 2010, 62, 701-725
190. Lockless, S. W.; Ranganathan, R. Evolutionary conserved pathways of energetic connectivity in protein families Science 1999, 286, 295-299 (Pubitemid 29484693)
191. Datta, D.; Scheer, J. M.; Romanowski, M. J.; Wells, J. A. An allosteric circuit in caspase-1 J. Mol. Biol. 2008, 381, 1157-1167
192. Liu, J.; Perumal, N. B.; Oldfield, C. J.; Su, E. W.; Uversky, V. N.; Dunker, A. K. Intrinsic disorder in transcription factors Biochemistry 2006, 45, 6873-6888 (Pubitemid 43856673)
193. Hilser, V. J.; Thompson, E. B. Intrinsic disorder as a mechanism to optimize allosteric coupling in proteins Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 8311-8315 (Pubitemid 47175484)
194. Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric modulators of GPCRs: taking advantage of permissive receptor pharmacology Trends Pharmacol. Sci. 2007, 28, 382-389 (Pubitemid 47087967)
195. 4 muscarinic acetylcholine receptor Mol. Pharmacol. 2011, 79, 855-865
196. Lu, J. Y. L.; Yang, Y.; Gnacadja, G.; Christopoulos, A.; Reagan, J. D. Effect of the calcimimetic R-568 on correcting inactivating mutations in the human calcium-sensing receptor J. Pharmacol. Exp. Ther. 2009, 331, 775-786
197. 4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms J. Biol. Chem. 2010, 285, 19012-19021
198. Kennedy, J. P.; Williams, L.; Bridges, T. M.; Daniels, R. N.; Weaver, D.; Lindsley, C. W. Application of combinatorial chemistry science on modern drug discovery J. Comb. Chem. 2008, 10, 345-354
199. Hopkins, A. L.; Groom, C. R. The druggable genome Nat. Rev. Drug Discovery 2002, 1, 727-730 (Pubitemid 37361545)
200. Maudsley, S.; Martin, B.; Luttrell., L. M. The origins of diversity and specificity in G protein-coupled receptor signaling J. Pharmacol. Exp. Ther. 2005, 314, 485-494 (Pubitemid 41043828)
201. McLoughlin, D. J.; Bertelli, F.; Williams, C. The A, B, Cs of G protein-coupled receptor pharmacologyin assay development for HTS Expert Opin. Drug Discovery 2007, 2, 603-619 (Pubitemid 47071655)
202. Wood, M. R.; Hopkins, C. R.; Brogan, J. T.; Conn, P. J.; Lindsley, C. W. "Molecular switches" on allosteric ligands that modulate modes of pharmacology Biochemistry 2011, 50, 2403-2140
203. 1 positive allosteric modulators Bioorg. Med. Chem. Lett. 2010, 20, 531-536
204. Sharma, S.; Rodriguez, A.; Conn, P. J.; Lindsley, C. W. Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl) pyrimidine scaffold Bioorg. Med. Chem. Lett. 2008, 18, 4098-4101
205. Sharma, S.; Kedrowski, J.; Rook, J. M.; Smith, J. M.; Jones, C. K.; Rodriguez, A. L.; Conn, P. J.; Lindsley, C. W. Discovery of molecular switches that modulate modes of mGluR5 pharmacology in vitro and in vivo within a series of functionalized 5-(phenylethynyl)pyrimidines J. Med. Chem. 2009, 52, 4103-4106
206. 5 NAMs, PAMs, and partial antagonists Bioorg. Med. Chem. Lett. 2011, 21, 2711-2714
207. Schann, S.; Mayer, S.; Franchet, C.; Frauli, M.; Steinberg, E.; Thomas, M.; Baron, L.; Neuville, P. Chemical switch of a metabotropic glutamate receptor 2 silent allosteric modulator into dual metabotropic glutamate receptor 2/3 negative/positive allosteric modulators J. Med. Chem. 2010, 53, 8775-8779
208. Pecknold, J. C.; McClure, D. J.; Appeltauer, L.; Wrzesinski, L.; Allan, T. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study J. Clin. Psychopharmacol. 1982, 2, 129-132
209. Berry-Kravis, E. M.; Hessl, D.; Coffey, S.; Hervey, C.; Schneider, A.; Yuhas, J.; Hutchinson, J.; Snape, M.; Tranfaglia, M.; Nguyen, D. V.; Hagerman, R. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome J. Med. Genet. 2009, 46, 266-271
210. http://www.neuropharm.co.uk/aboutus/portfolio-pipeline/ fragile-x-programme.
211. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Inf. 2009, 23, 1-50.
212. Keywood, C.; Wakefield, M.; Tack, J. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastroesophageal reflux disease Gut 2009, 58, 1192-1199
213. Marin, J. C. A.; Goadsby, P. J. Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine? Expert Opin. Invest. Drugs 2010, 19, 555-561
214. Goadsby, P. J.; Keywood, C. G. Investigation of the role of mGluR5 Inhibition in Migraine: A Proof of Concept Study of ADX10059 in Acute Treatment of Migraine. Abstracts of Papers, 61st Annual Meeting of the American Academy of Neurology, Seattle, WA, 2009; American Academy of Neurology: St. Paul, MN; Abstract P06.006.
215. Addex Pharmaceuticals: Addex Announces ADX10059 Phase IIa Acute Anxiety Data. Press Release, January 3, 2008.
216. Bessis, A.-S.; Bolea, C.; Bonnet, B.; Epping-Jordan, M.; Poirier, N.; Poli, S.-M.; Rocher, J.-P.; Thollon, Y. Novel Alkynyl Derivatives as Modulators of Metabotropic Glutamate Receptors. Int. Pat. Appl. WO 2005/123703, 2005.
217. Addex Pharmaceuticals: Addex Initiates Phase IIa Clinical Trial of Dipraglurant-IR in Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID). Press Release, March 31, 2011.
218. Rouzade-Dominguez, M.-L.; Pfannkuche, H.-J.; Gasparini, F. Use of mGluR5 (ESP. AFQ056) in GI (ESP. GERD). Int. Pat. Appl. WO 2007/006530, 2007.
219. Gasparini, F. mGluR5 Antagonists as Potential Symptomatic Therapy for Fragile X Disorder. Abstracts of Papers, 239th National Meeting of the American Chemical Society, San Francisco, CA; American Chemical Society: Washingtion, DC; Abstract MEDI 12031.
220. Berg, D.; Godau, J.; Trenkwalder, C.; Eggert, K.; Csoti, I.; Storch, A.; Gasparini, F.; Hariry, S.; Johns, D.; Gomez-Mancilla, B. A Randomized, Controlled Trial Evaluating AFQ056 in Reducing Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease. Abstracts of Papers, 13th International Congress of Parkinson's Disease and Movement Disorders, Paris, France; The Movement Disorder Society: Milwaukee, WI, 2009; Abstract LB-05.
221. Novartis: Planned filings 2011 to ≥2015. Novartis Second Quarter 2011 Results, Novartis Investor Presentation, July 19, 2011.
222. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/results?term=AFQ056.
223. Harris, G. Promise seen in drug for retardation syndrome. New York Times 2010, April 30) A1.
224. AstraZeneca: NCEs phases I and II and development pipeline: discontinued projects vs July 29, 2010. AstraZeneca Development Pipeline (January 27, 2011).
225. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/results?term= AZD2066.
226. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/results?term= AZD2516.
227. F. Hoffman-LaRoche Ltd.: Roche Pipeline 2010. Pipeline Summary (April 15, 2010).
228. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/results?term=RO4917523.
229. Seaside Therapeutics: Novel Therapies for Patients with Autism and Fragile X Syndrome. Corporate Fact Sheet, Quarter 1 (2010).
230. Seaside Therapeutics. Compounds. http://www.seasidetherapeutics.com/ compounds.